CureVac (CVAC) to Release Earnings on Tuesday

CureVac (NASDAQ:CVAC) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect CureVac to post earnings of $0.67 per share for the quarter.

CureVac (NASDAQ:CVAC) last released its earnings results on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. The firm had revenue of $15.55 million during the quarter, compared to analysts’ expectations of $10.07 million. On average, analysts expect CureVac to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Stock Performance

Shares of CVAC stock opened at $2.80 on Friday. CureVac has a 12 month low of $2.21 and a 12 month high of $6.30. The company has a current ratio of 2.29, a quick ratio of 2.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $626.86 million, a PE ratio of -2.11, a price-to-earnings-growth ratio of 1.92 and a beta of 2.61. The company’s fifty day moving average price is $2.96 and its 200-day moving average price is $3.25.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a research report on Monday, September 16th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.